Mexiletine Hydrochloride



Indications and Reactions:

Role Indications Reactions
Primary
Ventricular Tachycardia 20.3%
Torsade De Pointes 14.5%
Disease Recurrence 11.6%
Neuralgia 8.7%
Arrhythmia 7.2%
Cardiac Failure 7.2%
Long Qt Syndrome Congenital 5.8%
Ventricular Extrasystoles 5.8%
Pain 4.3%
Prophylaxis 4.3%
Adverse Event 2.9%
Lung Adenocarcinoma Stage Iv 2.9%
Long Qt Syndrome 1.4%
Myotonia 1.4%
Suicide Attempt 1.4%
Drug Ineffective 17.2%
Syncope 13.8%
Skin Exfoliation 10.3%
Drug Rash With Eosinophilia And Systemic Symptoms 6.9%
Skin Ulcer 6.9%
Ventricular Fibrillation 6.9%
Dizziness 3.4%
Drug Effect Decreased 3.4%
Dysarthria 3.4%
Leukocytosis 3.4%
Mental Status Changes 3.4%
Myocardial Infarction 3.4%
Rash Generalised 3.4%
Rash Maculo-papular 3.4%
Swelling Face 3.4%
Virus Serology Test Positive 3.4%
Wrong Technique In Drug Usage Process 3.4%
Secondary
Product Used For Unknown Indication 13.7%
Drug Use For Unknown Indication 13.0%
Ventricular Tachycardia 12.2%
Arrhythmia 8.4%
Pain 6.9%
Cancer Pain 4.6%
Ventricular Extrasystoles 4.6%
Gastritis 3.8%
Anxiety Disorder 3.1%
Back Pain 3.1%
Constipation 3.1%
Disease Recurrence 3.1%
Neuralgia 3.1%
Tachycardia 3.1%
Torsade De Pointes 3.1%
Cerebral Infarction 2.3%
Cytomegalovirus Infection 2.3%
General Anaesthesia 2.3%
Hypothyroidism 2.3%
Nausea 2.3%
Ventricular Tachycardia 11.4%
Drug Ineffective 8.6%
Alopecia Totalis 5.7%
Drug Eruption 5.7%
Neutrophil Count Decreased 5.7%
Pneumonia 5.7%
Pyrexia 5.7%
Rash 5.7%
Rash Maculo-papular 5.7%
Skin Exfoliation 5.7%
Syncope 5.7%
White Blood Cell Count Increased 5.7%
Blood Creatinine Increased 2.9%
Dysarthria 2.9%
Erythema 2.9%
Erythema Multiforme 2.9%
Extrasystoles 2.9%
Hepatic Function Abnormal 2.9%
Hodgkin's Disease 2.9%
Liver Injury 2.9%
Concomitant
Drug Use For Unknown Indication 33.4%
Product Used For Unknown Indication 31.1%
Hiv Infection 3.4%
Hypertension 2.8%
Pain 2.8%
Prophylaxis 2.7%
Behcet's Syndrome 2.6%
Pulmonary Arterial Hypertension 2.6%
Arrhythmia 2.4%
Ventricular Tachycardia 2.3%
Nuclear Magnetic Resonance Imaging 2.1%
Hypokalaemia 2.0%
Acute Promyelocytic Leukaemia 1.9%
Multiple Myeloma 1.6%
Cardiac Failure 1.5%
Depression 1.4%
Rheumatoid Arthritis 1.0%
Insomnia 0.9%
Dialysis 0.8%
Nausea 0.8%
Vomiting 11.1%
Ventricular Tachycardia 10.3%
Nausea 7.7%
White Blood Cell Count Increased 7.7%
Therapeutic Agent Toxicity 6.0%
Weight Decreased 6.0%
Drug Effect Decreased 5.1%
Neonatal Respiratory Distress Syndrome 5.1%
White Blood Cell Count Decreased 5.1%
Wound Infection 4.3%
Altered State Of Consciousness 3.4%
Anaemia 3.4%
Death 3.4%
Leukopenia 3.4%
Pneumonia 3.4%
Pyrexia 3.4%
Ventricular Extrasystoles 3.4%
Atrial Flutter 2.6%
Conversion Disorder 2.6%
Drug Eruption 2.6%